Abstract 6119
Background
Cancer nursing is required to identify potential advances in nursing practice, assess their relevance for ones own particular clinical situation, gather opinion on any potential change in practice (both locally and farther afield), integrate this into practice, evaluate success and then disseminate the learning from this process. Until relatively recently this process could be reasonably laborious and slow moving. However, the advent of social media sites and software and their use in nursing has streamlined this process making the gathering, group analysis and dissemination of clinical information faster and more intuitive. This study considers the authors own experience in using two social media sites (Twitter and Facebook) to gather and share clinical infomation as part of the UK Oncology Nursing Society and when setting up a new Members Interest Group for UK Lead Cancer Nurses.
Methods
This piece describes the use of Twitter and Facebook group as a professional tool to -: 1) Gather cancer nursing opinion on a particular subject (case study - Streamlining MDT Working in England and the contrubution of specialist Nursing) - potentially a ’digitall Delphi Technique’ using Twitter and Facebook 2) Build group cohesion, ask clinical questions, share information and practice and build relationships within a newly established UK group of Lead Cancer Nurses. The experiences of UKONS members of using social media professionally will be gathered, the clinical effectivenes of using social media to gather nursing opinion on a particular nursing problem (streamlining MDT working) will be analysed.
Results
The experiences of cancer nurses in using social media in professional settings will be presented as part of an overall narrative and key themes will be presented and discussed Number and range of responses to a clinical question posed on social media will be presented with consideration of how effective a tool Twitter is in gathering clinical opinion and driving improvement. Ths will be presented numerically and graphically.
Conclusions
The positive impact of the professional use of social media will be presented. Potential uses and fine tuning of these tools in cancer nursing will be considered Potential pitfalls and negative effects will also be considered.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
4506 - Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity
Presenter: Adel Samson
Session: Poster Display session 3
Resources:
Abstract
1631 - Randomized phase 2 clinical trial of NY-ESO-1 protein vaccine combined with cholesteryl pullulan (CHP-NY-ESO-1) in resected esophageal cancer patients
Presenter: Shinichi Kageyama
Session: Poster Display session 3
Resources:
Abstract
4244 - T cell repertoire sequencing reveals dynamics of response to dendritic cell vaccine plus dasatinib for checkpoint blockade resistant metastatic melanoma
Presenter: Luca Quagliata
Session: Poster Display session 3
Resources:
Abstract
5791 - Ixovex, a novel oncolytic E1B-mutated adenovirus
Presenter: Mohiemen Anwar
Session: Poster Display session 3
Resources:
Abstract
4170 - Anti-CSPG4 DNA vaccination as a promising strategy for the treatment of CSPG4+ tumors: a comparative oncology trial
Presenter: Federica Riccardo
Session: Poster Display session 3
Resources:
Abstract
5780 - Antitumor activity, immunogenicity and safety of a novel PD-1 vaccine in combination with two chimeric HER-2 peptide vaccine in syngeneic Balb/c, C57Bl/6 models and in beagle dogs
Presenter: Pravin Kaumaya
Session: Poster Display session 3
Resources:
Abstract
5860 - Maternal immunization against ALK as a weapon to fight neuroblastoma
Presenter: Giuseppina Barutello
Session: Poster Display session 3
Resources:
Abstract
4720 - Phase 1 study evaluating safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-428, first-in-class mesothelin (MSLN)-CD40 bispecific, in patients (pts) with advanced solid tumors
Presenter: Jason Luke
Session: Poster Display session 3
Resources:
Abstract
5717 - Anti-PD-L1/IL-15 fusion protein generates robust adaptive immune gene signatures in tumors leading to tumor inhibition and memory responses
Presenter: Stella Martomo
Session: Poster Display session 3
Resources:
Abstract
1802 - Evaluation of the anti-tumor efficacy and immune effects of N-809, a novel IL-15 superagonist/anti-PD-L1 bispecific agent
Presenter: Kristin Hicks
Session: Poster Display session 3
Resources:
Abstract